Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
Egypt: New Treatments May Defuse Viral Hepatitis Time Bomb

Egypt is said officially to have the highest prevalence of hepatitis C in the world, with 10 to 14 percent of its 85 million people infected, and about two million in dire need of treatment. The Egyptian government recently struck a deal with U.S. pharmaceutical firm Gilead Sciences to purchase its new hepatitis C pill Sovaldi at a fraction of its American price.

Published
10 April 2014
From
Inter Press Service
Gilead aims to license hepatitis C drug to 3-4 Indian firms

Gilead Sciences aims to license its new hepatitis C drug Sovaldi to three or four Indian generic manufacturers to allow sales of the medicine at lower prices in some 60 developing nations.

Published
09 April 2014
From
Reuters
Gilead says has discounted hepatitis C drug for some health plans

Gilead Sciences Inc, under fire for pricing a new hepatitis C drug at $1,000 a pill, has discount agreements with a number of health insurers, a company executive said in an interview.

Published
31 March 2014
From
Reuters
Interferon-free BMS combo cures 90% of genotype 1 hepatitis C

An all-oral regimen of daclatasvir, asunaprevir and BMS-791325 – without interferon or ribavirin – led to sustained response in approximately 90% of people with hepatitis C virus

Published
26 March 2014
By
Liz Highleyman
Gilead offers Egypt new hepatitis C drug at 99 percent discount

Gilead Sciences, facing mounting criticism over the high price of its new hepatitis C pill Sovaldi, has offered to supply the medicine to Egypt at a 99 percent discount to the U.S. price. While the drug will still cost $900 for a 12-week course of treatment, that is a fraction of the $84,000 charged for a course of treatment in the United States.

Published
24 March 2014
From
Reuters
US Lawmakers Attack Cost of New Hepatitis Drug

A new drug to treat hepatitis C that costs $1,000 a pill has caused rising concern among insurers and state Medicaid programs. It has now also spurred interest from Democratic congressmen whose queries about the drug prompted a sell-off in biotechnology stocks on Friday.

Published
24 March 2014
From
New York Times
Merck combination suppresses HCV in mono-infected and co-infected patients

An all-oral combination of the hepatitis C virus (HCV) protease inhibitor MK-5172 and NS5A inhibitor MK-8742, with or without ribavirin, demonstrated promising end-of-treatment viral suppression in people

Published
21 March 2014
By
Liz Highleyman
Trouble Ahead for Gilead and Sovaldi?

Atop ever-inflating sales estimates for Gilead Science's blockbuster Sovaldi, patent battles also continue to crop up. Late last week Idenix Pharmaceuticals added three more suits to the pile, filing in France, Germany and the UK for patent infringement on nucleosides, a precursor to the compound in Sovaldi. This is in addition to two lawsuits it has pending against Gilead stateside since late last year.

Published
19 March 2014
From
Motley Fool
How Much Should Hepatitis C Treatment Cost?

A new pill to treat hepatitis C raises difficult questions about fair pricing, not only in the United States and other affluent nations but in developing countries around the world.

Published
18 March 2014
From
New York Times (editorial)
Hepatitis C treatments: Australia urged to subsidise 'revolutionary' new drugs

Public health experts say effective new drugs to treat hepatitis C should be subsidised in Australia to avert a looming strain on the national health system.

Published
18 March 2014
From
ABC Online

Filter by country